Literature DB >> 24264960

Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

Camilo Molino Guidoni1, Paulo Roque Obreli-Neto, Leonardo Regis Leira Pereira.   

Abstract

Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions. To analyze the profile of pharmacoepidemiological drug prescriptions for warfarin in patients admitted to a Brazilian tertiary hospital. In the cross sectional study the electronic prescriptions of the January 01, 2004-December 31, 2010 of patients using warfarin of the Clinical Hospital of the Faculty of Medicine of Ribeirao Preto were analyzed. Sociodemographic characteristics, clinical data, laboratory test results, and drug therapy data were collected. We identified 3,048 patients who received 154,161 drug prescriptions, 42,120 of which contained warfarin. The mean age was 55.8 ± 19.3 years, 48.2% were elderly, and 4.3% had specific cerebrovascular disease diagnoses. The average International Normalized Ratio (INR; 2.4 ± 1.7) and warfarin dose (5.1 ± 1.8 mg/day) were within therapeutic protocol recommendations. However, approximately 14.0 and 8.5% of the patients had mean INR greater than 3.0 and 3.5, respectively. In addition, 66.4 and 6.1% of the patients received polypharmacy and clopidogrel, respectively, which can increase the risk of drug-drug interactions and bleeding. The average number of drugs per prescription was 7.2 ± 3.8, and 31,595 drug prescriptions (74.0%) consisted of five or more drugs. The study found a high prevalence of elderly patients, polypharmacy, and concomitant use of anticoagulant and antiplatelet drugs, which may favor the occurrence of adverse events.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24264960     DOI: 10.1007/s11239-013-1030-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

Review 1.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

2.  Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system.

Authors:  Paulo Roque Obreli Neto; Alessandro Nobili; Srecko Marusic; Diogo Pilger; Camilo Molino Guidoni; André de Oliveira Baldoni; Joice Mara Cruciol-Souza; Alessandra Negri Da Cruz; Walderez Penteado Gaeti; Roberto Kenji Nakamura Cuman
Journal:  J Pharm Pharm Sci       Date:  2012       Impact factor: 2.327

3.  Warfarin in valvulopathy: how important is seniority?

Authors:  Max Grinberg
Journal:  Arq Bras Cardiol       Date:  2013-05       Impact factor: 2.000

4.  Major bleeding risk associated with warfarin and co-medications in the elderly population.

Authors:  Agnes I Vitry; Elizabeth E Roughead; Emmae N Ramsay; Adrian K Preiss; Philip Ryan; Andrew L Gilbert; Gillian E Caughey; Sepehr Shakib; Adrian Esterman; Ying Zhang; Robyn A McDermott
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-10       Impact factor: 2.890

5.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.

Authors:  E M Hylek; Y C Chang; S J Skates; R A Hughes; D E Singer
Journal:  Arch Intern Med       Date:  2000-06-12

6.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 7.  Practical issues, limitations, and periprocedural management of the NOAC's.

Authors:  Gregory Connolly; Alex C Spyropoulos
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

8.  Warfarin prevalence, indications for use and haemorrhagic events.

Authors:  W Ouirke; M Cahill; K Perera; J Sargent; J Conway
Journal:  Ir Med J       Date:  2007-03

9.  Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.

Authors:  Priccila Zuchinali; Gabriela C Souza; Graziella Aliti; Mariana R Botton; Lívia Goldraich; Katia G Santos; Mara H Hutz; Eliane Bandinelli; Luis E Rohde
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

10.  Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation.

Authors:  James A Nelson; John P Vavalle; Christopher H May; Aijing Zhang; L Kristin Newby; Linda K Shaw; Sana M Al-Khatib; John H Alexander; Christopher B Granger; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

View more
  1 in total

1.  Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis.

Authors:  Mahin Delara; Lauren Murray; Behnaz Jafari; Anees Bahji; Zahra Goodarzi; Julia Kirkham; Mohammad Chowdhury; Dallas P Seitz
Journal:  BMC Geriatr       Date:  2022-07-19       Impact factor: 4.070

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.